Haw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich

Simply Wall St.08-16

Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2659179626?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-08-16 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659179626","market":"nz","top_or_hot":-1,"title":"Haw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich","media":"Simply Wall St.","content":"<div>\n<p>Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in...</p>\n\n<a href=\"https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-16 04:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in...</p>\n\n<a href=\"https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMDE","symbol_name":"PGIM S&P 500 Max Buffer ETF - December","start_time":0,"source_url":"https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti","article_id":"2659179626","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659179626","pubTimestamp":1786825883,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in this half-year period is profitability. Net income of about S$107.9m on revenue of S$115.9m translates into very high margins, which matters far more than the soft share price tape.\nFor short term traders the drift in Haw Par may look uninspiring. For long term holders the focus is now on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMDE":"PGIM S&P 500 Max Buffer ETF - December","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","RGLO":"Global Equity Active ETF","H02.SI":"虎豹企业","VGFPF":"Vanguard Funds PLC","GXDW":"Global X Dorsey Wright Thematic ETF","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","VOTE":"TCW Transform 500 ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","BK6506":"制药与医学研究概念","BK6079":"制药","IE0031814969.USD":"FSSA ASEAN ALL CAP FUND \"I\" (USD) ACC"},"translate_title":"Haw Par (SGX:H02) 股票走低，但利润率仍然异常丰厚","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMDE":0.78,"GXDW":0.78,"DECU":0.78,"FEBU":0.78,"VOTE":0.78,"JOYT":0.78,"H02.SI":1.5,"VGFPF":0.78,"RGLO":0.78},"content_text":"Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in this half-year period is profitability. Net income of about S$107.9m on revenue of S$115.9m translates into very high margins, which matters far more than the soft share price tape. For short term traders the drift in Haw Par may look uninspiring. For long term holders the focus is now on whether those rich margins and the current valuation can hold over the coming years. Love Haw Par's rich margins but uneasy about the recent share price drift? Check out the 299 resilient stocks with low risk scores as a benchmark for stocks that pair resilience with stronger market support. AdvertisementH1 2026 Earnings Summary  Revenue H1 2026: S$115.925m vs. H1 2025 S$126.342m (a softer period with lower reported revenue) Net Income H1 2026: S$107.867m vs. H1 2025 S$144.142m (net profit was lower than in the prior half year) Basic EPS H1 2026: S$0.487 per share vs. H1 2025 S$0.651 per share (earnings per share declined on this comparison) Trailing 12 month Net Income to Revenue Margin H1 2026: S$229.187m net income vs. S$219.55m revenue (a very high trailing margin, reported as materially higher than the prior year)  Prefer clean visual charts instead of scrolling through dense earnings tables for Haw Par? View a full picture of its margin profile and profitability history in an easy-to-scan format through the company report for Haw Par.. SGX:H02 Trailing 12-Month Earnings & Revenue History as at Aug 2026 Haw Par margins keep bullish story alive For investors leaning positive on Haw Par, the latest half keeps the focus firmly on profitability. Net income of S$107.9m on S$115.9m revenue leaves very wide margins intact. The trailing 12 month net income of S$229.2m against S$219.6m revenue also points to strong earnings power over a longer window, even after a softer H1. That supports the idea of a brand backed, asset supported group where earnings quality, rather than rapid top line expansion, sits at the centre of the bullish argument. Soft top line feeds into the cautious view The bearish side will highlight that H1 2026 revenue and net income are both lower than H1 2025, while the share price has fallen about 8% over 90 days. That lines up with concerns that Haw Par may not see a straight line in earnings across cycles and that the market remains unconvinced. Even with very strong margins, the step down in profit and earnings per share keeps alive worries about how resilient each business segment is when conditions are less supportive. After a period of softer revenue and a dividend that is not well covered by free cash flows, it is fair to ask whether Haw Par has other structural vulnerabilities that are not obvious from headline margins alone. Review the independent risk analysis for Haw Par which shows 1 important warning sign Take Control Of Your Next Move If Haw Par's strong margins but softer recent share price have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more appealing entry point. When you decide to take a position, use the Portfolio Command Center to keep your holdings organised and surface only the most important developments. For a broader view on Haw Par and similar stocks, tap into the Community to compare your thinking with thousands of other investors. This way you can spot hidden catalysts or emerging risks early and stay a step ahead of the market. Seeking Alternatives Beyond Haw Par? Fresh stock ideas can start moving fast once momentum builds. Use these focused shortlists before the crowd catches on and information goes stale. Get in early.  Spot companies with strong cash generation and sturdy balance sheets by scanning the curated list of solid balance sheet and fundamentals stocks (434 results) that highlights businesses built to handle pressure while others are dropping. Capture emerging earnings momentum in AI by checking the hand picked 76 profitable AI stocks that aren't just burning cash that filters for real cash generation instead of stocks simply flying on hype alone. Identify income opportunities before yields get compressed by reviewing the carefully selected 437 dividend fortresses that focuses on payouts designed to stand up when conditions turn.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Haw Par might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659179626","isCrawlerRequest":true}